Acorn Capital Advisors
Latest statistics and disclosures from Acorn Capital Advisors's latest quarterly 13F-HR filing:
- Top 5 stock holdings are CGON, URGN, YMAB, TRVI, CADL, and represent 56.34% of Acorn Capital Advisors's stock portfolio.
- Added to shares of these 8 stocks: YMAB, AURA, CADL, TRVI, VYNE, BCAX, OPTN, CYBN.
- Started 1 new stock position in AURA.
- Reduced shares in these 2 stocks: MURA, Aadi Bioscience.
- Acorn Capital Advisors was a net buyer of stock by $5.7M.
- Acorn Capital Advisors has $150M in assets under management (AUM), dropping by -19.31%.
- Central Index Key (CIK): 0002054410
Tip: Access up to 7 years of quarterly data
Positions held by Acorn Capital Advisors consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Acorn Capital Advisors
Acorn Capital Advisors holds 22 positions in its portfolio as reported in the March 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Cg Oncology (CGON) | 18.5 | $28M | 1.1M | 24.50 |
|
|
| Urogen Pharma (URGN) | 11.2 | $17M | 1.5M | 11.06 |
|
|
| Y Mabs Therapeutics (YMAB) | 9.6 | $14M | +13% | 3.2M | 4.43 |
|
| Trevi Therapeutics (TRVI) | 9.0 | $14M | +7% | 2.1M | 6.29 |
|
| Candel Therapeutics (CADL) | 8.1 | $12M | +10% | 2.2M | 5.65 |
|
| Puma Biotechnology (PBYI) | 7.8 | $12M | 3.9M | 2.96 |
|
|
| Bicara Therapeutics (BCAX) | 5.6 | $8.4M | 643k | 13.03 |
|
|
| Protara Therapeutics Com Stk (TARA) | 3.6 | $5.5M | 1.3M | 4.26 |
|
|
| Terns Pharmaceuticals (TERN) | 3.6 | $5.4M | 2.0M | 2.76 |
|
|
| Onkure Therapeutics Class A Com (OKUR) | 3.4 | $5.1M | 1.4M | 3.56 |
|
|
| Verastem (VSTM) | 3.1 | $4.7M | 780k | 6.03 |
|
|
| Cybin Com New (CYBN) | 3.1 | $4.7M | 734k | 6.35 |
|
|
| Cardiff Oncology (CRDF) | 3.0 | $4.5M | 1.4M | 3.14 |
|
|
| Optinose Com New (OPTN) | 2.6 | $3.9M | 423k | 9.17 |
|
|
| Aadi Bioscience | 1.4 | $2.0M | 1.1M | 1.78 |
|
|
| X4 Pharmaceuticals (XFOR) | 1.2 | $1.8M | 7.3M | 0.24 |
|
|
| Mural Oncology (MURA) | 1.1 | $1.6M | 1.3M | 1.26 |
|
|
| Aura Biosciences (AURA) | 1.0 | $1.5M | NEW | 591k | 2.46 |
|
| Bioatla (BCAB) | 0.9 | $1.4M | 4.0M | 0.35 |
|
|
| Q32 Bio (QTTB) | 0.9 | $1.3M | 803k | 1.65 |
|
|
| Vyne Therapeutics (VYNE) | 0.8 | $1.2M | +71% | 786k | 1.58 |
|
| Acrivon Therapeutics Common Stock (ACRV) | 0.5 | $823k | 405k | 2.03 |
|
Past Filings by Acorn Capital Advisors
SEC 13F filings are viewable for Acorn Capital Advisors going back to 2024
- Acorn Capital Advisors 2024 Q4 restated filed May 19, 2025
- Acorn Capital Advisors 2025 Q1 restated filed May 19, 2025
- Acorn Capital Advisors 2025 Q1 filed May 15, 2025
- Acorn Capital Advisors 2024 Q4 amended filed May 7, 2025